Pyronaridine–Artesunate versus Mefloquine plus Artesunate for Malaria - Rueangweerayut, Ronnatrai; Phyo, Aung Pyae; Uthaisin, Chirapong; Poravuth, Yi; Binh, Tran Quang; Tinto, Halidou; Pénali, Louis K; Valecha, Neena; Tien, Nong Thi; Abdulla, Salim; Borghini-Fuhrer, Isabelle; Duparc, Stephan; et al. (The New England journal of medicine, 2012)
Keywords: Adolescent; Adult; Africa; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antimalarials - administration & dosage; Antimalarials - adverse effects; Antimalarials - therapeutic use; Antiparasitic agents; Artemisinin; Artemisinins - administration & dosage; Artemisinins - adverse effects; Artemisinins - therapeutic use; Artesunate; Asia; Biological and medical sciences; Body weight; Child; Child, Preschool; Drug Combinations; Drug dosages; Drug Resistance; Female; General aspects; Genotyping; Human protozoal diseases; Humans; Infectious diseases; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver; Malaria; Malaria, Falciparum - drug therapy; Male; Medical sciences; Mefloquine; Mefloquine - administration & dosage; Mefloquine - adverse effects; Mefloquine - therapeutic use; Middle Aged; Motivation; Naphthyridines - administration & dosage; Naphthyridines - adverse effects; Naphthyridines - therapeutic use; Parasites; Parasitic diseases; Participation; Patients; Pharmaceutical industry; Pharmacology. Drug treatments; Plasmodium falciparum; Proportional Hazards Models; Protozoal diseases; Pyronaridine; Seizures; Substance abuse treatment; Young Adult; Cambodia; Infection; Medicine; Antimalarial; Protozoal disease; Drug combination; Mefloquine; Malaria; Pyronaridine; Artesunate; Parasiticide; Parasitosis; Comparative study